Close
  Indian J Med Microbiol
 

Figure 4: a) Pretreatment biopsy with increased CD11c- and CD11c+LC3- positive DC (Double IHC, x400); b) Follow-up biopsy at 6 months showing reducti on in CD11c- and CD11c+LC3-positi ve DC (Double IHC, x200); c) LC3 cytoplasm dot positi ve DC (Double IHC, x1000); d) Pretreatment biopsy showing increased CD86- and CD86+LC3-positi ve DC (Double IHC, x200); e) Follow-up biopsy at 6 months shows reduced CD86- and CD86+LC3-positi ve DC (Double IHC, x200) and f) CD11c+MAP1LC3A in control showing few positi ve DCs (Double IHC, x400)

Figure 4: a) Pretreatment biopsy with increased CD11c- and CD11c+LC3- positive DC (Double IHC, x400); b) Follow-up biopsy at 6 months showing reducti on in CD11c- and CD11c+LC3-positi ve DC (Double IHC, x200); c) LC3 cytoplasm dot positi ve DC (Double IHC, x1000); d) Pretreatment biopsy showing increased CD86- and CD86+LC3-positi ve DC (Double IHC, x200); e) Follow-up biopsy at 6 months shows reduced CD86- and CD86+LC3-positi ve DC (Double IHC, x200) and f) CD11c+MAP1LC3A in control showing few positi ve DCs (Double IHC, x400)